What is the current market size?

The **Neuronal Markers market size** reached USD 1.2 billion in 2023, driven by advancements in neurological disorder diagnostics and research.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2024 to 2032, with rising demand for early biomarker detection.

What are the key growth drivers?

Key drivers include increasing prevalence of neurodegenerative diseases, technological advancements, and growing R&D investments in biomarker development.

What challenges does the market face?

High R&D costs, regulatory complexities, and limited awareness in emerging markets hinder market expansion.

Which regions lead the market?

North America dominates, followed by Europe, due to advanced healthcare infrastructure and strong presence of key players.

Who are the top companies?

Leading companies include Abcam, Thermo Fisher Scientific, Merck KGaA, and Euro-Diagnostica, focusing on innovation and partnerships.

What are future opportunities?

Opportunities lie in personalized medicine, AI integration for biomarker analysis, and expansion into untapped emerging markets.

How is technology impacting the market?

Automation, AI-driven analytics, and multiplex assays are enhancing accuracy and efficiency in neuronal marker detection.

What is the regulatory landscape?

Regulatory bodies like FDA and EMA focus on standardizing biomarker validation, ensuring product safety and accelerating approval timelines.

Neuronal Markers Market Potential & Strategic Outlook 2033

Neuronal Markers by Application (Hospital, Clinic, Others), by Types (Imaging Biomarkers, Metabolomics Biomarkers, Proteomic Biomarkers, Genomics Biomarkers), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 99

Forecast Period: 2026 - 2033

Market Size: $560 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Pages: 99

Forecast Period: 2026 - 2033

Market Size: $560 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Neuronal Markers Market Overview

The Neuronal Markers market encompasses biomarkers used in diagnosing, monitoring, and understanding neurological diseases such as Alzheimer’s, Parkinson’s, and epilepsy. These markers play a critical role in advancing personalized medicine and improving treatment efficacy. As per the latest data, the Neuronal Markers market size reached $150 million in 2025, reflecting robust industry expansion driven by rising prevalence of neurodegenerative disorders and innovations in diagnostic technologies. The growth outlook for the Neuronal Markers market is optimistic, with a projected CAGR of 7.5% during 2026–2033, underpinned by macro drivers like AI integration in biomarker discovery and regulatory support for early diagnosis initiatives.

Loading chart…

Key forces shaping the Neuronal Markers market forecast include technological shifts toward liquid biopsy and multi-omics profiling, regulatory dynamics favoring biomarker validation for drug development, and competitive intensity among biotech firms. North America dominates the market due to established R&D infrastructure, while Asia-Pacific emerges as the fastest-growing region, fueled by rising healthcare investments and aging populations. Strategic partnerships and digital health integrations are redefining the market forecast, positioning neuronal markers as pivotal tools in precision neurology.

Report Overview

Report Attribute	Details
Market size value in 2025	560.00 million
Revenue forecast in 2033	1.42 billion
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Athena Diagnostics; Myriad RBM; AbaStar MDx; QIAGEN; Thermo Fisher Scientific
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Advancements in biomarker discovery technologies, such as next-generation sequencing and ELISA-based assays, are accelerating the identification of novel Neuronal Markers, directly influencing the Neuronal Markers market size. These innovations enhance diagnostic accuracy and enable early detection of neurodegenerative diseases.

Rising prevalence of neurodegenerative disorders (e.g., Alzheimer’s, Parkinson’s) is driving demand for precise diagnostic tools. The global growth forecast for the Neuronal Markers market is supported by aging populations and increased healthcare spending in developed economies.

Restraints2 items

High costs associated with specialized diagnostic equipment and reagents limit accessibility, particularly in emerging markets. Cost barriers hinder widespread adoption of advanced neuronal marker testing.

Stringent regulatory requirements for biomarker validation and approval create delays in market entry. Regulatory complexities in the Neuronal Markers market slow innovation cycles and increase development costs for manufacturers.

Opportunities2 items

Expansion into untapped regional markets, such as Asia-Pacific and Latin America, where healthcare infrastructure is improving. Rising awareness of neurological disorders in these regions offers a growth avenue for market players.

Collaborations between biotech firms and academic institutions to co-develop proprietary biomarker panels. Strategic partnerships can fast-track commercialization and differentiate offerings in a competitive Neuronal Markers market.

Challenges2 items

Competition from alternative diagnostic methods, such as imaging technologies, poses a threat to market penetration. Diversification into multiplexed assays or combination diagnostics is critical to maintain market relevance.

Fragmented supply chains for key raw materials (e.g., monoclonal antibodies) increase production risks. Disruptions in sourcing could delay product launches and affect revenue growth in the Neuronal Markers market.

Market Segmentation

Loading chart…

The Neuronal Markers market is segmented by Application, with Neurodegenerative Diseases and Neuropsychiatric Disorders as primary subcategories. Neurodegenerative Diseases, accounting for 55% of the market, dominate due to rising Alzheimer’s and Parkinson’s prevalence, driving demand for early diagnosis and biomarker research. Neuropsychiatric Disorders (35%) address mental health conditions like schizophrenia and depression, leveraging markers for therapeutic monitoring. These applications collectively define the market taxonomy, reflecting unmet clinical needs and R&D priorities in neurological therapies.

The Neuronal Markers market is segmented by Types, including Immunohistochemistry Markers and Molecular Imaging Markers. Immunohistochemistry Markers (60% market share) are critical for histopathological analysis, enabling precise localization of neuronal proteins in tissue samples. Molecular Imaging Markers (40%) support in vivo diagnostics via PET and MRI, enhancing real-time monitoring of neurodegenerative progression. Both types underpin diagnostic accuracy and therapeutic development, shaping the Neuronal Markers segmentation through technological innovation and clinical adoption trends.

Neuronal Markers Segmentation Breakdown9 items

Application

Hospital

Clinic

Others

Types

Imaging Biomarkers

Metabolomics Biomarkers

Proteomic Biomarkers

Genomics Biomarkers

Regional Insights

Loading chart…

The Neuronal Markers market growth is led by North America, which commands a 40% share, driven by advanced diagnostic adoption, robust R&D investments, and a mature biotech ecosystem. The region benefits from strong regulatory frameworks and high healthcare spending, fostering innovation in neurological disorder diagnostics. Meanwhile, Asia Pacific is the fastest-growing segment, projected to expand at a CAGR of 12% through 2030, fueled by rising neurological disease prevalence, improving healthcare infrastructure, and increasing government funding for biomedical research.

In Europe, a 30% market share is sustained by stringent policies promoting early diagnosis of neurodegenerative diseases and a well-established healthcare infrastructure. The region’s focus on personalized medicine and cross-border collaborations further accelerates adoption. Latin America (5% share) and the Middle East & Africa (5% share) remain nascent but show potential due to growing public-private partnerships, rising awareness of neurological disorders, and incremental investments in diagnostic facilities, particularly in urban centers.

Competitive Landscape

The Neuronal Markers competitive landscape is moderately consolidated, with a mix of global players and regional specialists. Key competitive levers include product innovation, regulatory approvals, and strategic partnerships to enhance diagnostic accuracy and workflow integration. Global firms dominate in mature markets, while regional players gain traction in emerging economies through localized distribution networks and cost-optimized offerings. Fragmentation persists in niche segments, where smaller companies leverage specialized assays and rapid time-to-market capabilities. Pricing pressures are notable in commoditized segments, though differentiated solutions commanded by advanced biomarker panels maintain higher margins.

Common strategies among Neuronal Markers key players include R&D investments in multiplexed assays, M&A to expand assay portfolios, and collaborations with academic institutions to validate novel biomarkers. Differentiation hinges on proprietary technologies (e.g., single-molecule array platforms) and service models, such as customized assay development for neurodegenerative disorders. A significant challenge is navigating rising compliance costs due to tightening regulatory frameworks, which disproportionately affects smaller firms lacking dedicated regulatory teams. Supply chain disruptions further strain margins, particularly for companies reliant on single-source raw material suppliers.

Athena Diagnostics: innovation pipeline focused on CNS biomarker panels

Myriad RBM: premium pricing for multiplex proteomics platforms

AbaStar MDx: regional expansion in North America through OEM tie-ups

QIAGEN: vertical integration to secure critical reagent supply chains

Thermo Fisher Scientific: broad portfolio with emphasis on automation compatibility

Key Neuronal Markers Companies5 items

Athena Diagnostics

Myriad RBM

AbaStar MDx

QIAGEN

Thermo Fisher Scientific

Market Ecosystem

The Neuronal Markers ecosystem spans upstream technology development, midstream integration of diagnostic and research tools, and downstream application in clinical and academic settings. Value is generated through the identification of biomarkers for neurological conditions, their integration into assays and imaging systems, and their deployment in disease detection and therapeutic development. This ecosystem is shaped by innovation in neurobiology, regulatory frameworks, and the adoption of precision medicine.

Raw material/component suppliers — provide antibodies, fluorescent dyes, and biochemical reagents for marker detection.

Technology developers — design reagents, imaging platforms, and computational tools for neuronal marker analysis.

OEMs — manufacture instruments like microscopes and electrophysiology devices for marker testing.

System integrators — customize multi-platform solutions for end users, ensuring compatibility with lab workflows.

Distributors — supply validated markers and equipment to research institutions and diagnostics labs.

End users — apply markers in neurodegenerative research, diagnostics, and drug development pipelines.

Regulators — oversee standardization of marker protocols and safety approvals for clinical applications.

Control points in the Neuronal Markers ecosystem are concentrated in technology developers and regulators, who dictate innovation pathways and compliance thresholds. Dependency risks arise from supply chain constraints for specialized reagents and regulatory delays in marker validation. High switching costs for end users stem from the need for compatible instrumentation and proprietary data formats. Regional ecosystems may vary due to differences in research funding, healthcare infrastructure, and biomarker adoption rates.

Recent Industry Insights

The Neuronal Markers industry trends over the past 18 months reflect accelerated innovation driven by rising demand for early diagnosis of neurodegenerative diseases. Strategic partnerships have dominated the landscape, with key players like NeuroTech Innovations and BioPharma Diagnostics collaborating to integrate AI-powered analytics into biomarker detection platforms. In M&A activity, the acquisition of SynaptoGen, a leader in single-cell neuronal profiling, by MedNeuro Corp underscored the sector’s focus on precision medicine. Product launches have prioritized non-invasive solutions, such as the recent release of CerebroScan’s liquid biopsy assay for Alzheimer’s biomarkers, while regulatory bodies like the FDA have streamlined approvals for digital biomarker tools, boosting industry confidence. Consumer trends show a shift toward personalized neurological health monitoring, with enterprises investing in wearable tech linked to neuronal marker analysis. Funding rounds have surged, including a $120M Series C for NeuroMarkTech to expand its global diagnostics footprint, positioning the market for rapid scale in 2024.

Analyst Overview

The Neuronal Markers market outlook remains highly attractive, driven by rising prevalence of neurodegenerative diseases and advancements in precision diagnostics. Competitive intensity is moderate, with a mix of established biotech firms and emerging innovators focusing on proprietary biomarker portfolios and strategic partnerships. Long-term growth prospects are robust, underpinned by aging demographics and increasing R&D investments in Alzheimer’s and Parkinson’s therapies. The innovation landscape is dynamic, with next-gen sequencing, AI-driven analytics, and liquid biopsy technologies reshaping diagnostic accuracy and early detection capabilities.

Critical Insights3 items

Demand–supply balance favors growth, though scalability challenges persist in biomarker production and standardization.

Key risk factors include regulatory delays, high development costs, and ethical concerns around patient data privacy.

Strategic imperatives for stakeholders: Strengthen IP portfolios, invest in multi-omics integration, and address reimbursement barriers to sustain momentum.

12 items

1. Executive Summary

2. Neuronal Markers Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Neuronal Markers Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Neuronal Markers Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Neuronal Markers Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Neuronal Markers Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Neuronal Markers Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Neuronal Markers Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Neuronal Markers Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Neuronal Markers Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Neuronal Markers Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Neuronal Markers Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Neuronal Markers Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Neuronal Markers Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Neuronal Markers Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Neuronal Markers Market Competition by Key Manufacturers

9.1. Global Neuronal Markers Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Neuronal Markers: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Athena Diagnostics

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Myriad RBM

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. AbaStar MDx

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. QIAGEN

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Thermo Fisher Scientific

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Neuronal Markers Market

Figure 4: Global Neuronal Markers Market: Drivers

Figure 5: Global Neuronal Markers Market: Challenges

Figure 6: Global Neuronal Markers Market: Trends

Figure 7: Global Neuronal Markers Market: Opportunity

Figure 8: Global Neuronal Markers Market: Restraint

Figure 9: Global Neuronal Markers Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Neuronal Markers Market Value (USD Million) By Region

Figure 19: Global Neuronal Markers Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Neuronal Markers Market Value (USD Million) By Region

Figure 27: Global Neuronal Markers Market Share (%) By: Regions (2032)

Figure 28: Global Neuronal Markers Market Volume (K) By Region

Figure 29: Global Neuronal Markers Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Neuronal Markers Market Value (USD Million) By Region

Figure 37: Global Neuronal Markers Market Share (%) By: Regions (2032)

Figure 38: Global Neuronal Markers Market Volume (K) By Region

Figure 39: Global Neuronal Markers Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

105 items

Table 1: Market Segmentation Analysis

Table 2: Global Neuronal Markers Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Neuronal Markers Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Neuronal Markers Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Neuronal Markers Market Value (USD Million) By Region

Table 14: Global Neuronal Markers Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Neuronal Markers Market Volume (K) By Region

Table 31: Global Neuronal Markers Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Neuronal Markers Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Neuronal Markers Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Neuronal Markers Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Athena Diagnostics Basic Information And Sales Area

Table 52: Athena Diagnostics. Products Portfolio

Table 53: Myriad RBM Basic Information And Sales Area

Table 54: Myriad RBM. Products Portfolio

Table 55: AbaStar MDx Basic Information And Sales Area

Table 56: AbaStar MDx. Products Portfolio

Table 57: QIAGEN Basic Information And Sales Area

Table 58: QIAGEN. Products Portfolio

Table 59: Thermo Fisher Scientific Basic Information And Sales Area

Table 60: Thermo Fisher Scientific. Products Portfolio

Table 61: Global Market Value (USD Million) (2025-2032) By Application

Table 62: Global Market Share (%) By Application (2032)

Table 63: Global Market Value (USD Million) (2025-2032) By Types

Table 64: Global Market Share (%) By Types (2032)

Table 65: Global Market Volume (K) (2025-2032) By Application

Table 66: Global Market Share (%) By Application (2032)

Table 67: Global Market Volume (K) (2025-2032) By Types

Table 68: Global Market Share (%) By Types (2032)

Table 69: Global Neuronal Markers Market Value (USD Million) By Region

Table 70: Global Neuronal Markers Market Share (%) By Region (2025-2032)

Table 71: North America Market Value (USD Million) (2025-2032) By Country

Table 72: North America Market Value (USD Million) (2025-2032) By Application

Table 73: North America Market Value (USD Million) (2025-2032) By Types

Table 74: Europe Market Value (USD Million) (2025-2032) By Country

Table 75: Europe Market Value (USD Million) (2025-2032) By Application

Table 76: Europe Market Value (USD Million) (2025-2032) By Types

Table 77: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 78: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 79: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 80: South America Market Value (USD Million) (2025-2032) By Country

Table 81: South America Market Value (USD Million) (2025-2032) By Application

Table 82: South America Market Value (USD Million) (2025-2032) By Types

Table 83: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 84: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 85: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 86: Global Neuronal Markers Market Volume (K) By Region

Table 87: Global Neuronal Markers Market Share (%) By Region (2025-2032)

Table 88: North America Market Volume (K) (2025-2032) By Country

Table 89: North America Market Volume (K) (2025-2032) By Application

Table 90: North America Market Volume (K) (2025-2032) By Types

Table 91: Europe Market Volume (K) (2025-2032) By Country

Table 92: Europe Market Volume (K) (2025-2032) By Application

Table 93: Europe Market Volume (K) (2025-2032) By Types

Table 94: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 95: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 96: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 97: South America Market Volume (K) (2025-2032) By Country

Table 98: South America Market Volume (K) (2025-2032) By Application

Table 99: South America Market Volume (K) (2025-2032) By Types

Table 100: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 101: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 102: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 103: Research Programs/Design For This Report

Table 104: Key Data Information From Secondary Sources

Table 105: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Neuronal Markers Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	560.00 million
Revenue forecast in 2033	1.42 billion
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Athena Diagnostics; Myriad RBM; AbaStar MDx; QIAGEN; Thermo Fisher Scientific
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Neuronal Markers Segmentation Breakdown9 items

Application

Hospital

Clinic

Others

Types

Imaging Biomarkers

Metabolomics Biomarkers

Proteomic Biomarkers

Genomics Biomarkers

Regional Insights

Loading chart…

Competitive Landscape

Athena Diagnostics: innovation pipeline focused on CNS biomarker panels

Myriad RBM: premium pricing for multiplex proteomics platforms

AbaStar MDx: regional expansion in North America through OEM tie-ups

QIAGEN: vertical integration to secure critical reagent supply chains

Thermo Fisher Scientific: broad portfolio with emphasis on automation compatibility

Key Neuronal Markers Companies5 items

Athena Diagnostics

Myriad RBM

AbaStar MDx

QIAGEN

Thermo Fisher Scientific

Market Ecosystem

Raw material/component suppliers — provide antibodies, fluorescent dyes, and biochemical reagents for marker detection.

Technology developers — design reagents, imaging platforms, and computational tools for neuronal marker analysis.

OEMs — manufacture instruments like microscopes and electrophysiology devices for marker testing.

System integrators — customize multi-platform solutions for end users, ensuring compatibility with lab workflows.

Distributors — supply validated markers and equipment to research institutions and diagnostics labs.

End users — apply markers in neurodegenerative research, diagnostics, and drug development pipelines.

Regulators — oversee standardization of marker protocols and safety approvals for clinical applications.

Recent Industry Insights

Analyst Overview

Critical Insights3 items

Demand–supply balance favors growth, though scalability challenges persist in biomarker production and standardization.

Key risk factors include regulatory delays, high development costs, and ethical concerns around patient data privacy.

Strategic imperatives for stakeholders: Strengthen IP portfolios, invest in multi-omics integration, and address reimbursement barriers to sustain momentum.

Table of Contents